The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 20, 2023

Filed:

May. 09, 2020
Applicant:

Celgene Quanticel Research, Inc., San Diego, CA (US);

Inventors:

Juan Manual Betancort, San Diego, CA (US);

Jeffrey Alan Stafford, San Diego, CA (US);

Ryan Stansfield, San Diego, CA (US);

James Marvin Veal, Apex, NC (US);

Assignee:

Celgene Quanticel Research, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/472 (2006.01); A61K 47/32 (2006.01); A61K 47/38 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61P 35/00 (2006.01); C07D 217/12 (2006.01); C07D 217/24 (2006.01); A61K 9/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/472 (2013.01); A61K 9/10 (2013.01); A61K 9/1635 (2013.01); A61K 9/1652 (2013.01); A61K 9/2054 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); A61P 35/00 (2018.01); C07D 217/12 (2013.01); C07D 217/24 (2013.01); A61K 9/1694 (2013.01); C07B 2200/13 (2013.01);
Abstract

Described herein is the bromodomain inhibitor 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one, including crystalline forms, amorphous forms, solvates, and hydrates thereof, as well as pharmaceutical compositions that include this bromodomain inhibitor. In some embodiments, the pharmaceutical composition comprises 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one that has been processed by micronization or spray dried dispersion. In some embodiments, the pharmaceutical composition further comprises at least one polymer. In some embodiments, the pharmaceutical composition comprises a solid polymer matrix comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one and at least one polymer. Pharmaceutical compositions comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one are useful for the treatment of cancer or neoplastic disease.


Find Patent Forward Citations

Loading…